Quigley Corporation Donates COLD-EEZE Lozenges to UNICEF in Response to Johns Hopkins Study on Zinc Gluconate

Copyright 1998 PR Newswire, Inc.
August 10, 1998


DOYLESTOWN, Pa., Aug. 10 /PRNewswire/ -- The Quigley Corporation (Nasdaq: QGLY) announced today that it has offered to donate 85,000 COLD-EEZE(R) lozenges to the United Nations Children's Emergency Fund (UNICEF) in response to the results of a new study conducted by the Johns Hopkins University School of Public Health. The six-month study of 609 children in urban India, conducted by Dr. Robert E. Black of the Johns Hopkins Department of International Health, and reported in the current issue of the electronic journal "Pediatrics," reported that children who were given zinc gluconate on a daily basis had a 45% drop in respiratory infection, mostly pneumonia. The study proves that a daily dosage of 10mg of Zinc Gluconate (Zinc Gluconate is the active ingredient of COLD-EEZE(R)) given to children in developing countries could save countless lives. This new study confirms once again the safety of Zinc Gluconate as the compound of choice. The results of this study have prompted the Company to explore the possibility of establishing an ongoing donation program to assist international and American relief agencies. Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition. The Quigley Corporation is the maker of COLD-EEZE(R), the only zinc gluconate glycine ZIGG(TM) lozenge proven in two double blind studies to reduce the duration and severity of the common cold symptoms. COLD-EEZE(R) is increasingly being used to reduce the symptoms of seasonal airborne allergies.

SOURCE: Quigley Corporation
Web Site: http://www.quigleyco.com
CONTACT: Karen Goldman of INFOCUS, 609-683-9055, ext. 106, for
Quigley.

Comments on this posting?

Click here to post a public comment on the Trash Talk Bulletin Board.

Click here to send a private comment to the Junkman.


Material presented on this home page constitutes opinion of Steven J. Milloy.
Copyright © 1998 Steven J. Milloy. All rights reserved on original material. Material copyrighted by others is used either with permission or under a claim of "fair use." Site developed and hosted by WestLake Solutions, Inc.
 1